Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Weight Loss 1Cachexia 1Advanced Cancer 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × olanzapine-fluoxetine combination × Clear all
NCT00489593 2015-01-08

Olanzapine in Patients With Advanced Cancer and Weight Loss

M.D. Anderson Cancer Center

Phase 1 Completed
57 enrolled

Cachexia, Weight Loss

NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed
25 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡